<div id="readability-page-1"><div><p>(MT Newswires) -- China's medical products administrator granted Beijing Foyou Pharma (SHA:601089) a drug registration certificate for its candesartan cilexetil and hydrochlorothiazide tablets for hypertension, according to a Tuesday filing with the Shanghai bourse.</p><p> The original manufacturer's candesartan cilexetil-hydrochlorothiazide tablets are not available in China. Takeda and AstraZeneca jointly developed the drug, the filing said.</p><p> The drug is indicated for patients with blood pressures not effectively controlled by just candesartan cilexetil or hydrochlorothiazide alone, among others.</p><p>Shares closed 2% higher on Tuesday.</p></div></div>

福元醫藥

<p>（MT Newswires）-- 根據週二在上海證券交易所的文件，中國醫療產品管理局已向北京福元醫藥（SHA:601089）頒發了其用於治療高血壓的氯沙坦西酯和氫氯噻嗪片的藥品註冊證書。原製造商的氯沙坦西酯 - 氫氯噻嗪片在中國並不可用。文件指出，該藥物由武田製藥和阿斯利康共同開發。該藥物適用於僅用氯沙坦西酯或氫氯噻嗪單獨治療效果不佳的高血壓患者等。週二股價上漲了 2%</p>

福元醫藥獲得中國高血壓藥片的藥品註冊許可